Transitions in Metabolic Syndrome and Metabolic Obesity Status over Time and Risk of Urologic Cancer: A Prospective Cohort Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Oct 21

PMID 39432545

Authors

Xia Wang

Runxue Jiang

Jianglun Shen

Shuohua Chen

Shouling Wu

Hailong Hu

Haifeng Cai

Affiliations

Soon will be listed here.

Abstract

Background And Aims: The effects of metabolic obesity (MO) phenotypes status and their dynamic changes on urologic cancer (UC) is ignored. We aimed to investigate the association between metabolic syndrome (MetS) and MO status at baseline, their dynamic changes and UC risk.

Methods: This paper studied 97,897 subjects who were free of cancers at baseline (2006-2007). Individuals were classified into four MO phenotypes by MetS and obesity at baseline. Transitions in MetS and MO status from 2006-2007 to 2008-2009 were considered. The hazard ratios (HRs) and 95% confidence intervals (CIs) for UC were assessed by multifactorial Cox proportional risk regression models. The main limitations of this study are as follows: the ratio of men to women in the cohort is unbalanced; the impacts of MetS and MO on each cancer type (kidney cancer, prostate cancer, bladder cancer) have not been analyzed separately; the transition intervals of MetS and MO phenotypes are relatively short.

Results: From baseline (2006-2007) survey to December 31, 2020, during a median follow-up of 14.02 years, 554 cases of UC were diagnosed. Participants with MetS [HRs (95% CI) = 1.26 (1.06-1.49)] and metabolically unhealthy obesity (MUO) [HRs (95% CI) = 1.49 (1.17-1.89)] had significantly higher risk of UC than those with non-MetS and metabolically healthy normal weight (MHN). Transitions in MetS and MO phenotypes over time were studied. Compared with non-MetS to non-MetS, the risks for UC in MetS to MetS [HRs (95% CI) = 1.45 (1.11-1.88)] was increased. Compared with MHN to MHN, both MUO to metabolically healthy obesity (MHO) [HRs (95% CI) = 2.65 (1.43-4.92)] and MUO to MUO [HRs (95% CI) = 1.60 (1.06-2.42)] had significantly higher UC risk.

Conclusions: MetS and MUO increased the UC risk at baseline. Transitions of MetS to MetS, MUO to MUO and even MUO to MHO over time significantly increased the risk of UC development.

Citing Articles

Exploring the impact of chronotype, chrononutrition and lifestyle on bladder cancer.

Strojny Z, Kawka E, Strojny M, Kucz-Chrostowska A, Zuraszek-Szymanska J, Sikora W Int Urol Nephrol. 2025; .

PMID: 39982656 DOI: 10.1007/s11255-025-04371-y.

Transitions in metabolic syndrome and metabolic obesity status over time and risk of urologic cancer: A prospective cohort study.

Wang X, Jiang R, Shen J, Chen S, Wu S, Hu H PLoS One. 2024; 19(10):e0311492.

PMID: 39432545 PMC: 11493304. DOI: 10.1371/journal.pone.0311492.

References

Zhou B . Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002; 15(1):83-96. View

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

Sun J, Zhao L, Yang Y, Ma X, Wang Y, Xiang Y . Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One. 2015; 10(3):e0119313. PMC: 4372289. DOI: 10.1371/journal.pone.0119313. View

Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin J, Friedman E, Slingerland J . Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017; 67(5):378-397. PMC: 5591063. DOI: 10.3322/caac.21405. View

Bellastella G, Scappaticcio L, Esposito K, Giugliano D, Maiorino M . Metabolic syndrome and cancer: "The common soil hypothesis". Diabetes Res Clin Pract. 2018; 143:389-397. DOI: 10.1016/j.diabres.2018.05.024. View

Guo S . Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol. 2013; 220(2):T1-T23. PMC: 4087161. DOI: 10.1530/JOE-13-0327. View

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View

Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B . Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007; 30(3):561-7. DOI: 10.2337/dc06-0922. View

Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm E, Danaei G . Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet. 2013; 383(9921):970-83. PMC: 3959199. DOI: 10.1016/S0140-6736(13)61836-X. View

10.

Mili N, Paschou S, Goulis D, Dimopoulos M, Lambrinoudaki I, Psaltopoulou T . Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021; 74(3):478-497. DOI: 10.1007/s12020-021-02884-x. View

11.

Rezaei F, Tabatabaee H, Rahmanian V, Mirahmadizadeh A, Hassanipour S . The Correlation Between Bladder Cancer and Obesity, Overweight, Physical Inactivity, and Tobacco Use: An Ecological Study in Asian Countries. Ann Glob Health. 2019; 85(1). PMC: 6634367. DOI: 10.5334/aogh.2545. View

12.

Li Z, Han H, Chang Y . Association between metabolic syndrome and the incidence of gastric cancer: a meta-analysis of cohort studies. Diabetol Metab Syndr. 2019; 11:83. PMC: 6785885. DOI: 10.1186/s13098-019-0478-y. View

13.

Montella M, Di Maso M, Crispo A, Grimaldi M, Bosetti C, Turati F . Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC Cancer. 2015; 15:720. PMC: 4609154. DOI: 10.1186/s12885-015-1769-9. View

14.

Nam G, Cho K, Han K, Kim C, Han B, Cho S . Obesity, abdominal obesity and subsequent risk of kidney cancer: a cohort study of 23.3 million East Asians. Br J Cancer. 2019; 121(3):271-277. PMC: 6738324. DOI: 10.1038/s41416-019-0500-z. View

15.

Li X, Chen H, Wang G, Feng X, Lyu Z, Wei L . Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. Front Oncol. 2019; 9:1047. PMC: 6811600. DOI: 10.3389/fonc.2019.01047. View

16.

Lyu Z, Li N, Wang G, Feng X, Chen S, Su K . Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. Int J Cancer. 2018; 144(12):2972-2984. DOI: 10.1002/ijc.32051. View

17.

Esposito K, Ciardiello F, Giugliano D . Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine. 2014; 46(1):39-42. DOI: 10.1007/s12020-013-0151-4. View

18.

Russo A, Autelitano M, Bisanti L . Metabolic syndrome and cancer risk. Eur J Cancer. 2007; 44(2):293-7. DOI: 10.1016/j.ejca.2007.11.005. View

19.

Kim J, Ahn S, Oh M, Moon D, Han K, Park H . Incidence of Prostate Cancer according to Metabolic Health Status: a Nationwide Cohort Study. J Korean Med Sci. 2019; 34(6):e49. PMC: 6374548. DOI: 10.3346/jkms.2019.34.e49. View

20.

Gati A, Kouidhi S, Marrakchi R, El Gaaied A, Kourda N, Derouiche A . Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict. Oncoimmunology. 2014; 3(1):e27810. PMC: 4010540. DOI: 10.4161/onci.27810. View